SODIUM PENTOBARBITAL (pentobarbital sodium) by Pfizer is clinical pharmacology barbiturates are capable of producing all levels of cns mood alteration from excitation to mild sedation, to hypnosis, and deep coma. First approved in 1974.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Barbiturates are capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia. Barbiturates depress the sensory cortex,…
Worked on SODIUM PENTOBARBITAL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.